Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration - Archive ouverte HAL Access content directly
Conference Papers Year :

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

ANNALS OF ONCOLOGY Volume: 30 Supplement: 5 Pages: 867-867 Meeting Abstract: LBA30_PR Published: OCT 2019

(1) , (2) , (3) , (2) , (4) , (5) , (6) , (7) , (2) , , (8) , (9) , , (10) , (11) , (12) , (13)
1
2
3
4
5
6
7
8
9
10
11
12
13

Domains

Life Sciences [q-bio]

Valerie TALY  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-02413130

Submitted on : Monday, December 16, 2019-9:58:07 AM

Last modification on : Friday, August 5, 2022-10:56:27 AM

Not file

Dates and versions

inserm-02413130 , version 1 (16-12-2019)

Identifiers

  • HAL Id : inserm-02413130 , version 1

Cite

Julien Taieb, Valérie Taly, Dewi Vernerey, Camille Bourreau, Jaafar Bennouna, et al.. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: SEP 27-OCT 01, 2019, Sep 2019, Barcelone, France. ⟨inserm-02413130⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-FCOMTE FNCLCC VALDAURELLE ICO GAUDUCHEAU USPC BS UNIV-MONTPELLIER IRCM SORBONNE-UNIVERSITE SU-MEDECINE UNIV-PARIS
118 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More